Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + dexamethasone + doxorubicin + vincristine
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This drug is a combination chemotherapy regimen consisting of four agents: cyclophosphamide, dexamethasone, doxorubicin, and vincristine. It is most commonly known as part of the "Hyper-CVAD" protocol (hyperfractionated cyclophosphamide, vincristine, doxorubicin [Adriamycin], and dexamethasone), which is used primarily in the treatment of hematologic malignancies such as acute lymphoblastic leukemia (ALL) and some types of lymphoma. Cyclophosphamide is an alkylating agent that crosslinks DNA to inhibit cell division; doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II; vincristine disrupts microtubule formation to arrest mitosis; dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects. The combination targets rapidly dividing cancer cells through multiple mechanisms including DNA damage, inhibition of mitosis, and modulation of immune response[1][2][5].
- Other names
- Hyper-CVAD
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on cyclophosphamide + dexamethasone + doxorubicin + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + dexamethasone + doxorubicin + vincristine.